• Home
  • Company Profile
  • News
  • Products
  • Cart
  • Checkout
  • My Account
  • Terms & Conditions
  • Privacy Policy
Paragon BioTeck, Inc.Paragon BioTeck, Inc.
  • HOME
  • ABOUT
    • Company Profile
    • Business Integrity
  • PRODUCTS
    • Diagnostics
      • Phenylephrine Hydrochloride Ophthalmic Solution USP 2.5% 15 mL
      • Phenylephrine Hydrochloride Ophthalmic Solution USP 2.5% 10mL
      • Phenylephrine Hydrochloride Ophthalmic Solution USP 10% 5mL
  • NEWS
  • CONTACT

Paragon BioTeck, Inc., Announces FDA Acceptance and Priority Review Designation of New Drug Application

Home » News » Paragon BioTeck, Inc., Announces FDA Acceptance and Priority Review Designation of New Drug Application

Paragon BioTeck, Inc., Announces FDA Acceptance and Priority Review Designation of New Drug Application

12/04/2012 Phenylephrine, Press Release

TIGARD, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, today announced that the New Drug Application (NDA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% to dilate the pupil has been accepted for review and granted Priority Review designation by the U.S. Food and Drug Administration (FDA). Paragon submitted the NDA in September 2012 under Section 505(b)(2) of the Food, Drug and Cosmetic Act.

Priority designation is given to therapies that offer potential major advances in treatment, including improved safety, or provide a treatment where no adequate therapy exists. Based upon the Prescription Drug User Fee Act (PDUFA), the FDA has set a target date of March 21, 2013 for FDA action on the NDA.

About Phenylephrine Hydrochloride Ophthalmic Solution

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is an alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly α-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial muscle of the iris.

Phenylephrine Hydrochloride Ophthalmic Solution Important Safety Information

Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis, as well as in pediatric patients under the age of one due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. It’s for topical ophthalmic use only, and not for injection.

Serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, some fatal, and significant elevations in blood pressure have been reported. Caution is advised in pediatric patients less than five years of age, and in patients with elevated blood pressure, cardiovascular disease or hyperthyroidism. Blood pressure should be monitored in patients with cardiovascular or endocrine disease. Rebound miosis has been reported one day after instillation.

Ocular adverse reactions include eye pain and stinging on instillation, temporary blurred vision and photophobia. Cardiovascular adverse reactions include increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage.

About Paragon BioTeck, Inc.

Paragon BioTeck, Inc., is a privately held ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight.

Share
0

You also might be interested in

Paragon BioTeck, Inc. Announces Call for 2018 Koch Kellan Scholarship Applicants

Oct 2, 2017

The Koch Kellan Scholarship honors a graduate medical student pursuing[...]

Xinxin Zhang shares her experience at ASCRS•ASOS

Jun 12, 2017

2017 Koch Kellan Scholar, Xinxin Zhang, was formally presented with her scholarship award at a ceremony held on Sunday, May 7. Ms. Zhang was invited to attend the 2017 ASCRS•ASOS annual meeting in Los Angeles on behalf of Paragon BioTeck where she had the opportunity to explore the conference and meet ophthalmic industry leaders. Read on to hear her thoughts about the conference and ceremony.

5 Questions: 2017 Koch Kellan Scholar Xinxin Zhang

May 23, 2017

Each year, Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to a third-year ophthalmology student. The scholarship, named for two pillars of the eye care industry — Paul Koch, MD, and Robert Kellan, MD — highlights rising stars who share our dedication to underserved medical needs. This year, we are proud to introduce our 2017 Koch Kellan Scholar: Xinxin Zhang. We caught up with her after the announcement to learn more about her exciting work and future plans.

RECENT POSTS

  • Paragon BioTeck Reformulated FRESHKOTE®, Prompting Eyevance Acquisition 09/14/2018
  • Paragon BioTeck, Inc. Hosts Pearl Buck Preschool Holiday Event 12/01/2017
  • Paragon BioTeck, Inc. Announces Call for 2018 Koch Kellan Scholarship Applicants 10/02/2017
  • Talking to Patients About Eye Health 08/24/2017
  • Xinxin Zhang shares her experience at ASCRS•ASOS 06/12/2017

Newsletter Sign-Up

  • This field is for validation purposes and should be left unchanged.

HOME

Contact Us
News

PRODUCTS

Diagnostics

ABOUT

Company Profile
Business Integrity

CUSTOMER SERVICE

1-888-424-1192
customercare@paragonbioteck.com

© 2017 Paragon BioTeck, Inc. All Rights Reserved.

Privacy Policy | Return Policy | Terms of Use | Social Media Guidelines


Next